Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2019

Open Access 01-12-2019 | Acute Coronary Syndrome | Review

Prognostic value of HbA1c for in-hospital and short-term mortality in patients with acute coronary syndrome: a systematic review and meta-analysis

Authors: Wenjun Pan, Haining Lu, Baotao Lian, Pengda Liao, Liheng Guo, Minzhou Zhang

Published in: Cardiovascular Diabetology | Issue 1/2019

Login to get access

Abstract

Background

HbA1c, the most commonly used indicator of chronic glucose metabolism, is closely associated with cardiovascular disease. However, the relationship between HbA1c and the mortality of acute coronary syndrome (ACS) patients has not been elucidated yet. Here, we aim to conduct a systematic review assessing the effect of HbA1c on in-hospital and short-term mortality in ACS patients.

Methods

Relevant studies reported before July 2019 were retrieved from databases including PubMed, Embase, and Central. Pooled relative risks (RRs) and the corresponding 95% confidence interval (CI) were calculated to evaluate the predictive value of HbA1c for the in-hospital mortality and short-term mortality.

Results

Data from 25 studies involving 304,253 ACS patients was included in systematic review. The pooled RR of in-hospital mortality was 1.246 (95% CI 1.113–1.396, p: 0.000, I2 = 48.6%, n = 14) after sensitivity analysis in studies reporting HbA1c as categorial valuable. The pooled RR was 1.042 (95% CI 0.904–1.202, p: 0.57, I2 = 82.7%, n = 4) in random-effects model for studies reporting it as continuous valuable. Subgroup analysis by diabetic status showed that elevated HbA1c is associated increased short-term mortality in ACS patients without diabetes mellitus (DM) history and without DM (RR: 2.31, 95% CI (1.81–2.94), p = 0.000, I2 = 0.0%, n = 5; RR: 2.56, 95% CI 1.38–4.74, p = 0.003, I2 = 0.0%, n = 2, respectively), which was not the case for patients with DM and patients from studies incorporating DM and non-DM individuals (RR: 1.16, 95% CI 0.79–1.69, p = 0.451, I2 = 31.9%, n = 3; RR: 1.10, 95% CI 0.51–2.38), p = 0.809, I2 = 47.4%, n = 4, respectively).

Conclusions

Higher HbA1c is a potential indicator for in-hospital death in ACS patients as well as a predictor for short-term mortality in ACS patients without known DM and without DM.
Appendix
Available only for authorised users
Literature
1.
Piironen M, Ukkola O, Huikuri H, Havulinna AS, Koukkunen H, Mustonen J, Ketonen M, Lehto S, Airaksinen J, Antero Kesaniemi Y, et al. Trends in long-term prognosis after acute coronary syndrome. Eur J Prev Cardiol. 2017;24(3):274–80.PubMedCrossRef
2.
Battistoni A, Rubattu S, Volpe M. Circulating biomarkers with preventive, diagnostic and prognostic implications in cardiovascular diseases. Int J Cardiol. 2012;157(2):160–8.PubMedCrossRef
3.
Eggers KM, Lindahl B. Prognostic biomarkers in acute coronary syndromes: risk stratification beyond cardiac troponins. Curr Cardiol Rep. 2017;19(4):29.PubMedPubMedCentralCrossRef
4.
Avanzini F, Mafrici A, Riva E, Franzosi MG, Milani V, Giudici V, Marelli G, Mariani G, Piatti PM, Roncaglioni MC, et al. A multicenter observational study on the management of hyperglycemia in patients with acute coronary syndrome. Nutr Metab Cardiovasc Dis. 2015;25(10):916–23.PubMedCrossRef
5.
Ambady R, Snehalatha C, Sathyamurthy I, Ravi MS, Nalini V, Vijay V, Tuomilehto J. High incidence of glucose intolerance in Asian-Indian subjects with acute coronary syndrome. Diabetes Care. 2005;28(10):2492–6.CrossRef
6.
de la Hera JM, Delgado E, Hernandez E, Garcia-Ruiz JM, Vegas JM, Avanzas P, Lozano I, Barriales-Villa R, Hevia S, Martin JS, et al. Prevalence and outcome of newly detected diabetes in patients who undergo percutaneous coronary intervention. Eur Heart J. 2009;30(21):2614–21.PubMedCrossRef
7.
Lee TF, Burt MG, Heilbronn LK, Mangoni AA, Wong VW, McLean M, Cheung NW. Relative hyperglycemia is associated with complications following an acute myocardial infarction: a post hoc analysis of HI-5 data. Cardiovasc Diabetol. 2017;16(1):157.PubMedPubMedCentralCrossRef
8.
Gu J, Pan JA, Fan YQ, Zhang HL, Zhang JF, Wang CQ. Prognostic impact of HbA1c variability on long-term outcomes in patients with heart failure and type 2 diabetes mellitus. Cardiovasc Diabetol. 2018;17(1):96.PubMedPubMedCentralCrossRef
9.
10.
Kmet M, Rajer B, Pernat A. Hemoglobin A1c is a better predictor of prognosis following the non-ST elevation acute coronary syndrome than fasting and admission glucose. Wien Klin Wochenschr. 2014;126(5–6):156–62.PubMedCrossRef
11.
Nichols GA, Joshua-Gotlib S, Parasuraman S. Glycemic control and risk of cardiovascular disease hospitalization and all-cause mortality. J Am Coll Cardiol. 2013;62(2):121–7.PubMedCrossRef
12.
Pararajasingam G, Hofsten DE, Logstrup BB, Egstrup M, Henriksen FL, Hangaard J, Egstrup K. Newly detected abnormal glucose regulation and long-term prognosis after acute myocardial infarction: comparison of an oral glucose tolerance test and glycosylated haemoglobin A1c. Int J Cardiol. 2016;214:310–5.PubMedCrossRef
13.
Malmberg K, Rydén L, Wedel H, Birkeland K, Bootsma A, Dickstein K, Efendic S, Fisher M, Hamsten A, Herlitz J, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J. 2005;26(7):650–61.PubMedCrossRef
14.
Bejan-Angoulvant T, Cornu C, Archambault P, Tudrej B, Audier P, Brabant Y, Gueyffier F, Boussageon R. Is HbA1c a valid surrogate for macrovascular and microvascular complications in type 2 diabetes? Diabetes Metab. 2015;41(3):195–201.PubMedCrossRef
15.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.PubMedCrossRef
16.
Yudkin JS, Oswald GA, McKeigue PM, Forrest RD, Jackson CA. The relationship of hospital admission and fatality from myocardial infarction to glycohaemoglobin levels. Diabetologia. 1988;31(4):201–5.PubMedCrossRef
17.
Cao JJ, Hudson M, Jankowski M, Whitehouse F, Weaver WD. Relation of chronic and acute glycemic control on mortality in acute myocardial infarction with diabetes mellitus. Am J Cardiol. 2005;96(2):183–6.PubMedCrossRef
18.
Britton KA, Aggarwal V, Chen AY, Alexander KP, Amsterdam E, Fraulo E, Muntner P, Thomas L, McGuire DK, Wiviott SD, et al. No association between hemoglobin A1c and in-hospital mortality in patients with diabetes and acute myocardial infarction. Am Heart J. 2011;161(4):657–663.e651.PubMedPubMedCentralCrossRef
19.
Chan CY, Li R, Chan JY, Zhang Q, Chan CP, Dong M, Yan BP, Lam YY, Yu CM. The value of admission HbA(1c) level in diabetic patients with acute coronary syndrome. Clin Cardiol. 2011;34(8):507–12.PubMedPubMedCentralCrossRef
20.
Cicek G, Uyarel H, Ergelen M, Ayhan E, Abanonu GB, Eren M, Gibson CM. Hemoglobin A1c as a prognostic marker in patients undergoing primary angioplasty for acute myocardial infarction. Coron Artery Dis. 2011;22(3):131–7.PubMedCrossRef
21.
Lazzeri C, Valente S, Chiostri M, Picariello C, Attanà P, Gensini GF. The prognostic impact of glycated hemoglobin in diabetic ST-elevation myocardial infarction. Int J Cardiol. 2011;151(2):250–2.PubMedCrossRef
22.
Lazzeri C, Valente S, Chiostri M, Picariello C, Attana P, Gensini GF. Glycated hemoglobin in ST-elevation myocardial infarction without previously known diabetes: its short and long term prognostic role. Diabetes Res Clin Pract. 2012;95(1):e14–6.PubMedCrossRef
23.
Liu Y, Yang YM, Zhu J, Tan HQ, Liang Y, Li JD. Haemoglobin A(1c), acute hyperglycaemia and short-term prognosis in patients without diabetes following acute ST-segment elevation myocardial infarction. Diabet Med. 2012;29(12):1493–500.PubMedCrossRef
24.
Blasco ML, Sanjuan R, Palacios L, Huerta R, Carratala A, Nunez J, Sanchis J. Prognostic value of admission glycated haemoglobin in unknown diabetic patients with acute myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2014;3(4):347–53.PubMedCrossRef
25.
Pusuroglu H, Akgul O, Cakmak HA, Erturk M, Surgit O, Celik O, Ozturk D, Uzun F, Akkaya E, Yildirim A. Long-term prognostic value of admission haemoglobin A1c(HbA1c) levels in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Postepy w Kardiologii Interwencyjnej. 2014;10(3):166–74.PubMedPubMedCentral
26.
Rousan TA, Pappy RM, Chen AY, Roe MT, Saucedo JF. Impact of diabetes mellitus on clinical characteristics, management, and in-hospital outcomes in patients with acute myocardial infarction (from the NCDR). Am J Cardiol. 2014;114(8):1136–44.PubMedCrossRef
27.
Abushady MM, Mohamady Y, Enany B, Nammas W. Prevalence of prediabetes in patients with acute coronary syndrome: impact on in-hospital outcomes. Intern Med J. 2015;45(2):183–8.PubMedCrossRef
28.
Aggarwal B, Shah GK, Randhawa M, Ellis SG, Lincoff AM, Menon V. Utility of glycated hemoglobin for assessment of glucose metabolism in patients with ST-segment elevation myocardial infarction. Am J Cardiol. 2016;117(5):749–53.PubMedCrossRef
29.
Samir S, Naseem M. Effect of admission glycometabolic state on clinical outcome in non diabetic subjects with acute st segment elevation myocardial infarction. Egypt J Crit Care Med. 2016;4(2):73–8.CrossRef
30.
Shin D, Ahn J, Cha KS, Park JS, Oh JH, Lee HW, Hong JY, Kim BW, Hong TJ. Impact of initial glycosylated hemoglobin level on cardiovascular outcomes in prediabetic patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Coron Artery Dis. 2016;27(1):40–6.PubMedCrossRef
31.
Fujino M, Ishihara M, Honda S, Kawakami S, Yamane T, Nagai T, Nakao K, Kanaya T, Kumasaka L, Asaumi Y, et al. Impact of acute and chronic hyperglycemia on in-hospital outcomes of patients with acute myocardial infarction. Am J Cardiol. 2014;114(12):1789–93.PubMedCrossRef
32.
Kim EJ, Jeong MH, Kim JH, Ahn TH, Seung KB, Oh DJ, Kim HS, Gwon HC, Seong IW, Hwang KK, et al. Clinical impact of admission hyperglycemia on in-hospital mortality in acute myocardial infarction patients. Int J Cardiol. 2017;236:9–15.PubMedCrossRef
33.
Oswald GA, Yudkinb JS. Hyperglycaemia following acute myocardial infarction The contribution of undiagnosed diabetes. Diabet Med. 1987;4:68–70.PubMedCrossRef
34.
Rasoul S, Ottervanger JP, Bilo HJ, Timmer JR, van ‘t Hof AW, Dambrink JH, Dikkeschei LD, Hoorntje JC, de Boer MJ, Zijlstra F. Glucose dysregulation in nondiabetic patients with ST-elevation myocardial infarction acute and chronic glucose dysregulation in STEMI. Neth J Med. 2007;65(3):95–100.PubMed
35.
Cakmak M, Cakmak N, Cetemen S, Tanriverdi H, Enc Y, Teskin O, Kilic ID. The value of admission glycosylated hemoglobin level in patients with acute myocardial infarction. Can J Cardiol. 2008;24(5):375–8.PubMedPubMedCentralCrossRef
36.
Timmer JR, Hoekstra M, Nijsten MW, van der Horst IC, Ottervanger JP, Slingerland RJ, Dambrink JH, Bilo HJ, Zijlstra F, van ‘t Hof AW. Prognostic value of admission glycosylated hemoglobin and glucose in nondiabetic patients with ST-segment-elevation myocardial infarction treated with percutaneous coronary intervention. Circulation. 2011;124(6):704–11.PubMedCrossRef
37.
Ahmad S, Ahmad S, Kashif M. Increasing HbA1C level; A prognostic indicator of increased thirty days mortality in patients of ST-Segment elevation in myocardial infarction. Pak J Med Health Sci. 2012;6(3):724–6.
38.
Tian L, Zhu J, Liu L, Liang Y, Li J, Yang Y. Hemoglobin A1c and short-term outcomes in patients with acute myocardial infarction undergoing primary angioplasty: an observational multicenter study. Coron Artery Dis. 2013;24(1):16–22.PubMedCrossRef
39.
40.
Heller SR, Bergenstal RM, White WB, Kupfer S, Bakris GL, Cushman WC, Mehta CR, Nissen SE, Wilson CA, Zannad F, et al. Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: the EXAMINE trial. Diabetes Obes Metab. 2017;19(5):664–71.PubMedPubMedCentralCrossRef
41.
Hermanides RS, Kennedy MW, Kedhi E, van Dijk PR, Timmer JR, Ottervanger JP, Dambrink JH, Gosselink AM, Roolvink V, Miedema K, et al. Impact of elevated HbA1c on long-term mortality in patients presenting with acute myocardial infarction in daily clinical practice: insights from a ‘real world’ prospective registry of the Zwolle Myocardial Infarction Study Group. Eur Heart J Acute Cardiovasc Care. 2019. https://​doi.​org/​10.​1177/​2048872619849921​.CrossRefPubMed
42.
Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet. 2000;355(9206):773–8.PubMedCrossRef
43.
Wang Z-B, Qiu C-G, Wang S-J, Han Z-Y, Huang Z-W, Sun G-J. Effect of hemoglobinA1C on the coronary flow velocity after percutaneous coronary intervention. Biomed Res. 2015;26(4):677–81.
44.
Ota S, Tanimoto T, Orii M, Hirata K, Shiono Y, Shimamura K, Matsuo Y, Yamano T, Ino Y, Kitabata H, et al. Association between hyperglycemia at admission and microvascular obstruction in patients with ST-segment elevation myocardial infarction. J Cardiol. 2015;65(4):272–7.PubMedCrossRef
45.
Iwakura K, Ito H, Ikushima M, Kawano S, Okamura A, Asano K, Kuroda T, Tanaka K, Masuyama T, Hori M, et al. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol. 2003;41(1):1–7.PubMedCrossRef
46.
Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Ryden L, Malmberg K. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet. 2002;359(9324):2140–4.PubMedCrossRef
47.
Østergaard HB, Mandrup-Poulsen T, Berkelmans GFN, van der Graaf Y, Visseren FLJ, Westerink J. Limited benefit of haemoglobin glycation index as risk factor for cardiovascular disease in type 2 diabetes patients. Diabetes Metab. 2019;45(3):254–60.PubMedCrossRef
48.
She J, Deng Y, Wu Y, Xia Y, Li H, Liang X, Shi R, Yuan Z. Hemoglobin A1c is associated with severity of coronary artery stenosis but not with long term clinical outcomes in diabetic and nondiabetic patients with acute myocardial infarction undergoing primary angioplasty. Cardiovasc Diabetol. 2017;16(1):97.PubMedPubMedCentralCrossRef
49.
Li XL, Li JJ, Guo YL, Zhu CG, Xu RX, Li S, Qing P, Wu NQ, Jiang LX, Xu B, et al. Relationship of glycated hemoglobin levels with myocardial injury following elective percutaneous coronary intervention in patients with type 2 diabetes mellitus. PLoS ONE. 2014;9(7):e101719.PubMedPubMedCentralCrossRef
50.
Kowalczyk J, Mazurek M, Zielinska T, Lenarczyk R, Sedkowska A, Swiatkowski A, Sredniawa B, Mencel G, Francuz P, Kalarus Z. Prognostic significance of HbA1c in patients with AMI treated invasively and newly detected glucose abnormalities. Eur J Prev Cardiol. 2015;22(6):798–806.PubMedCrossRef
51.
Savonitto S, Morici N, Nozza A, Cosentino F, Perrone Filardi P, Murena E, Morocutti G, Ferri M, Cavallini C, Eijkemans MJ, et al. Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes. Diabetes Vasc Dis Res. 2018;15(1):14–23.CrossRef
52.
Geng J, Zhang Y, Wang B, Xie J, Xu B, Li J. Glycosylated hemoglobin levels and clinical outcomes in nondiabetic patients with coronary artery disease. Medicine. 2017;96(17):e6784.PubMedPubMedCentralCrossRef
53.
Molgat AS, Tilokee EL, Rafatian G, Vulesevic B, Ruel M, Milne R, Suuronen EJ, Davis DR. Hyperglycemia inhibits cardiac stem cell-mediated cardiac repair and angiogenic capacity. Circulation. 2014;130(11 Suppl 1):S70–6.PubMedCrossRef
54.
Erickson JR, Pereira L, Wang L, Han G, Ferguson A, Dao K, Copeland RJ, Despa F, Hart GW, Ripplinger CM, et al. Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation. Nature. 2013;502(7471):372–6.PubMedPubMedCentralCrossRef
55.
56.
Zhang L, Xu C, Liu J, Bai X, Li R, Wang L, Zhou J, Wu Y, Yuan Z. Baseline plasma fibrinogen is associated with haemoglobin A1c and 2-year major adverse cardiovascular events following percutaneous coronary intervention in patients with acute coronary syndrome: a single-centre, prospective cohort study. Cardiovasc Diabetol. 2019;18(1):52.PubMedPubMedCentralCrossRef
57.
Li G, Hou X, Li Y, Zhang P, Zhao Q, Li J, Shi J. Prognostic value of glycated hemoglobin among patients with ST-segment elevation myocardial infarction: a systematic review and meta-analysis. Clin Chem Lab Med. 2017;55(8):1090–9.PubMedCrossRef
Metadata
Title
Prognostic value of HbA1c for in-hospital and short-term mortality in patients with acute coronary syndrome: a systematic review and meta-analysis
Authors
Wenjun Pan
Haining Lu
Baotao Lian
Pengda Liao
Liheng Guo
Minzhou Zhang
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2019
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-019-0970-6

Other articles of this Issue 1/2019

Cardiovascular Diabetology 1/2019 Go to the issue

Original investigation

Circulating microRNA-21 is an early predictor of ROS-mediated damage in subjects with high risk of developing diabetes and in drug-naïve T2D

Original investigation

Impaired branched chain amino acid oxidation contributes to cardiac insulin resistance in heart failure

Original investigation

The impact of body weight and diabetes on new-onset atrial fibrillation: a nationwide population based study

Original investigation

Visit-to-visit variability of glycemia and vascular complications: the Hoorn Diabetes Care System cohort

Original investigation

Altered bioavailability of epoxyeicosatrienoic acids is associated with conduit artery endothelial dysfunction in type 2 diabetic patients

Original investigation

Ipragliflozin-induced adipose expansion inhibits cuff-induced vascular remodeling in mice

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits